keyword
MENU ▼
Read by QxMD icon Read
search

Treatment-resistant Depression

keyword
https://www.readbyqxmd.com/read/29665520/treatment-resistant-depression-and-suicidality
#1
REVIEW
Isidoor O Bergfeld, Mariska Mantione, Martijn Figee, P Richard Schuurman, Anja Lok, Damiaan Denys
BACKGROUND: Thirty percent of patients with treatment-resistant depression (TRD) attempt suicide at least once during their lifetime. However, it is unclear what the attempted and completed suicide incidences are in TRD patients after initiating a treatment, and whether specific treatments increase or decrease these incidences. METHODS: We searched PubMed systematically for studies of depressed patients who failed at least two antidepressant therapies and were followed for at least three months after initiating a treatment...
April 3, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29664276/effects-of-n-n-dimethyltryptamine-dmt-on-rat-behaviors-relevant-to-anxiety-and-depression
#2
Lindsay P Cameron, Charlie J Benson, Lee E Dunlap, David E Olson
Depression and anxiety disorders are debilitating diseases resulting in substantial economic costs to society. Traditional antidepressants often take weeks to months to positively affect mood and are ineffective for about 30% of the population. Alternatives, such as ketamine, a dissociative anesthetic capable of producing hallucinations, and the psychoactive tisane ayahuasca have shown great promise due to their fast-acting nature and effectiveness in treatment-resistant populations. Here, we investigate the effects of N,N-dimethyltryptamine (DMT), the principle hallucinogenic component of ayahuasca, in rodent behavioral assays relevant to anxiety and depression using adult, male, Sprague-Dawley rats...
April 17, 2018: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29660639/elevated-tumor-necrosis-factor-alpha-receptor-subtype-1-and-the-association-with-abnormal-brain-function-in-treatment-resistant-depression
#3
Mao-Hsuan Huang, Mu-Hong Chen, Pei-Chi Tu, Ya Mei Bai, Tung-Ping Su, Bang-Hung Yang, Ren-Shyan Liu, Cheng-Ta Li
BACKGROUND: Major depressive disorder (MDD) patients have shown elevated plasma levels of pro-inflammatory biomarkers compared to healthy controls. We hypothesized increased serum tumor necrosis factor-alpha receptor subtype 1 (TNF-α R1) is more associated with impaired brain function in patients with treatment-resistant depression (TRD) than those without TRD. METHODS: 34 MDD patients and 34 healthy subjects were recruited and we separated MDD patients to TRD group (n = 20) and non-TRD (n = 14) group...
April 6, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29656032/bioenergetics-and-synaptic-plasticity-as-potential-targets-for-individualizing-treatment-for-depression
#4
REVIEW
J Blair Price, Carrie Bronars, Sophie Erhardt, Kathyrn R Cullen, Lilly Schwieler, Michael Berk, Ken Walder, Sean L McGee, Mark A Frye, Susannah J Tye
Disruptions of bioenergetic signaling and neurogenesis are hallmarks of depression physiology and are often the product of dysregulation of the inflammatory, stress-response, and metabolic systems. These systems are extensively interrelated at the physiological level, yet the bulk of the literature to date addresses pathophysiological mechanisms in isolation. A more integrated understanding of the etiology, progression, and treatment response profiles of depression is possible through wider consideration of relevant preclinical and clinical studies that examine the result of disruptions in these systems...
April 12, 2018: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/29655977/dexmedetomidine-or-fentanyl-cardiovascular-stability-and-analgesia-during-propofol-ketamine-total-intravenous-anaesthesia-in-experimental-pigs
#5
Andreas Lervik, Joanna Raszplewicz, Birgit Ranheim, Susanna Solbak, Simen F Toverud, Henning A Haga
OBJECTIVE: To compare cardiovascular function and response to nociception during total intravenous anaesthesia in pigs with propofol, ketamine and either dexmedetomidine or fentanyl administered as a continuous infusion. STUDY DESIGN: Blinded, randomized, balanced, crossover study ANIMALS: Eight immunocastrated male, mixed breed pigs with a mean ± standard deviation body weight of 26.4 ± 1.9 kg for dexmedetomidine and 27.5 ± 3.8 kg for fentanyl treatment...
December 5, 2017: Veterinary Anaesthesia and Analgesia
https://www.readbyqxmd.com/read/29649674/are-there-clinical-and-neurophysiologic-predictive-factors-for-a-positive-response-to-hf-rtms-in-patients-with-treatment-resistant-depression
#6
Anna Poleszczyk, Maria Rakowicz, Tadeusz Parnowski, Jakub Antczak, Łukasz Święcicki
Better selection of patients with treatment-resistant depression for high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) would make the procedure more efficient. The objective of this study was to search for clinical and neurophysiologic predictors of therapeutic response with a special focus on the bipolar population. Forty patients (30 bipolar) underwent 20 daily sessions of HF-rTMS. Clinical outcome measures included the 21-item Hamilton Depression Rating Scale, the Beck Depression Inventory, the Clinical Global Impression, and the Patient Global Impression...
April 3, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29642877/standardisation-framework-for-the-maudsley-staging-method-for-treatment-resistance-in-depression
#7
Abebaw Fekadu, Jacek G Donocik, Anthony J Cleare
BACKGROUND: Treatment-resistant depression (TRD) is a serious and relatively common clinical condition. Lack of consensus on defining and staging TRD remains one of the main barriers to understanding TRD and approaches to intervention. The Maudsley Staging Method (MSM) is the first multidimensional model developed to define and stage treatment-resistance in "unipolar depression". The model is being used increasingly in treatment and epidemiological studies of TRD and has the potential to support consensus...
April 11, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29628065/modulating-emotion-perception-opposing-effects-of-inhibitory-and-excitatory-prefrontal-cortex-stimulation
#8
Swantje Notzon, Christian Steinberg, Peter Zwanzger, Markus Junghöfer
BACKGROUND: Excitatory repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (dlPFC) is approved by the U.S. Food and Drug Administration for the treatment of adult patients with treatment-resistant major depressive disorder (MDD). This stimulation is supposed to restore excitability of prefrontal cortex regions that exhibit diminished regulation of emotion-generative systems in MDD. Based on the valence lateralization hypothesis, inhibitory rTMS of the right dlPFC has also been applied in MDD...
April 2018: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://www.readbyqxmd.com/read/29627920/advances-in-pharmacotherapy-of-late-life-depression
#9
REVIEW
John L Beyer, Kim G Johnson
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures...
April 7, 2018: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29626565/antidepressant-like-actions-by-silencing-of-neuronal-elav-like-rna-binding-proteins-hub-and-huc-in-a-model-of-depression-in-male-mice
#10
Maria Domenica Sanna, Alessandro Quattrone, Nicoletta Galeotti
Currently available antidepressant drugs often fail to achieve full remission and patients might evolve to treatment resistance, showing the need to achieve a better therapy of depressive disorders. Increasing evidence supports that post-transcriptional regulation of gene expression is important in neuronal development and survival and a relevant role is played by RNA binding proteins (RBP). To explore new therapeutic strategies, we investigated the role of the neuron-specific ELAV-like RBP (HuB, HuC, HuD) in a mouse model of depression...
April 4, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29626340/neuroimmune-biomarkers-in-mental-illness
#11
James W Herron, Louis Nerurkar, Jonathan Cavanagh
Exploration of neuroimmune mechanisms is vital to the understanding of the pathogenesis and pathophysiology of mental disorders. Inflammatory and immune mechanisms are increasingly understood to underpin a number of neuropsychiatric disorders, with an ever-expanding evidence base drawn from basic science to large-scale epidemiological data. Unravelling of these mechanisms should lead to biomarker discovery and potential new avenues for therapeutics that modulate immunological mechanisms. Identification of neuroimmune biomarkers is vital to improving diagnosis, stratification and treatment of mental disorders...
April 7, 2018: Current Topics in Behavioral Neurosciences
https://www.readbyqxmd.com/read/29621905/pharmacodynamic-and-pharmacokinetic-evaluation-of-buprenorphine-samidorphan-for-the-treatment-of-major-depressive-disorder
#12
Renee-Marie Ragguett, Carola Rong, Joshua D Rosenblat, Roger C Ho, Roger S McIntyre
Treatment resistant depression (TRD) represents approximately 20% of all individuals receiving care for major depressive disorder. The opioidergic system is identified as a novel target which hitherto has not been sufficiently investigated in adults with TRD. The combination product buprenorphine + samidorphan is an opioid modulatory agent which has demonstrated replicated evidence of efficacy in TRD without abuse liability. Areas covered: Databases Pubmed, Google Scholar and clinicaltrials.gov were searched from inception through December 2017 for clinical trial information, pharmacokinetics, and pharmacodynamics of buprenorphine + samidorphan...
April 6, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29621842/repetitive-transcranial-magnetic-stimulation-in-the-treatment-of-depression
#13
Saxby Pridmore, William Pridmore
BACKGROUND: Transcranial magnetic stimulation (TMS)is a treatment for major depressive disorder that is otherwise resistant to treatment. Although world-leading research in TMS has been conducted in Australia, where it has had some availability for two decades, there is limited familiarity with the treatment in the general medical community. Availability, however, is increasing. OBJECTIVE: The aim of this article is to inform general practitioners of some scientific and practical aspects of TMS treatment...
March 2018: Australian journal of general practice
https://www.readbyqxmd.com/read/29620558/effect-of-low-intensity-versus-high-intensity-resistance-training-on-the-functioning-of-the-institutionalized-frail-elderly
#14
Ulku K Sahin, Nuray Kirdi, Ergun Bozoglu, Aydin Meric, Galip Buyukturan, Ahmet Ozturk, Huseyin Doruk
Frailty has emerged as an important risk factor for disability. Age-related declines in physical and physiological function lead to increased risk of loss of independence and poor quality of life. Recent evidence has shown the effectiveness of physical exercise programmes in preventing or reversing frailty. The aim of this study was to evaluate changes in the functioning of frail elderly individuals after undergoing resistance training for 3 days a week for 8 weeks. The effectiveness of exercise training was investigated in 48 frail elderly individuals who were randomly assigned to the following intervention groups: high-intensity (HI; n=16; age: 69-96 years) or low-intensity (LI; n=16; age: 77-93 years) strength training groups or a control group (n=16; age: 76-93 years) with no specific exercise programme...
April 3, 2018: International Journal of Rehabilitation Research. Revue Internationale de Recherches de Réadaptation
https://www.readbyqxmd.com/read/29618967/closing-the-loop-on-deep-brain-stimulation-for-treatment-resistant-depression
#15
REVIEW
Alik S Widge, Donald A Malone, Darin D Dougherty
Major depressive episodes are the largest cause of psychiatric disability, and can often resist treatment with medication and psychotherapy. Advances in the understanding of the neural circuit basis of depression, combined with the success of deep brain stimulation (DBS) in movement disorders, spurred several groups to test DBS for treatment-resistant depression. Multiple brain sites have now been stimulated in open-label and blinded studies. Initial open-label results were dramatic, but follow-on controlled/blinded clinical trials produced inconsistent results, with both successes and failures to meet endpoints...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29618013/fgf21-is-associated-with-metabolic-effects-and-treatment-response-in-depressed-bipolar-ii-disorder-patients-treated-with-valproate
#16
Hui Hua Chang, Po See Chen, Yung Wen Cheng, Tzu-Yun Wang, Yen Kuang Yang, Ru-Band Lu
Background: Patients with bipolar disorder are at high risk of metabolic disturbance after mood stabilizer treatment. However, the mediators linking the two conditions remain unknown. In this study, we investigated whether fibroblast growth factor-21 (FGF21) was associated with metabolic effects and treatment response in depressed bipolar disorder patients. Methods: We recruited 78 community-dwelling controls and 137 bipolar disorder patients; the latter were interviewed using the Chinese Version of the Modified Schedule of Affective Disorder and Schizophrenia-Life Time...
April 1, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29615471/pharmacological-characterizations-of-h05-a-novel-potent-serotonin-and-noradrenaline-reuptake-inhibitor-with-moderate-5-ht2a-antagonist-activity-for-anti-depression
#17
Xiangqing Xu, Yaqin Wei, Qiang Guo, Song Zhao, Zhiqiang Liu, Ting Xiao, Yani Liu, Yinli Qiu, Yuanyuan Hou, Guisen Zhang, Kewei Wang
Multi-target antidepressants selectively inhibiting monoaminergic transporters and 5-HT2A receptors have demonstrated higher efficacy and fewer side effects than selective serotonin reuptake inhibitors (SSRIs). In the present study, we synthesized a series of novel 3-(benzo[d] [1, 3] dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which H05 was identified as a lead compound with potent inhibition effects on both serotonin (Ki=4.81 nM) and norepinephrine (Ki=6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50=60...
April 3, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29613946/clinical-predictors-of-response-to-magnetic-seizure-therapy-in-depression-a-preliminary-report
#18
Sarah Kayser, Bettina H Bewernick, Stefanie Wagner, Thomas E Schlaepfer
OBJECTIVES: Magnetic seizure therapy (MST) is a novel convulsive brain stimulation method in clinical testing, which is used as an alternative for electroconvulsive therapy in patients with treatment-resistant depression (TRD). Preliminary studies have suggested that MST leads to fewer cognitive adverse effects than electroconvulsive therapy but has similar efficacy. However, the clinical predictors of response to MST have not been evaluated yet. This study aimed to investigate whether these predictors can be identified in patients with TRD...
April 2, 2018: Journal of ECT
https://www.readbyqxmd.com/read/29613944/neurocognitive-effects-of-repetitive-transcranial-magnetic-stimulation-with-a-2-coil-device-in-treatment-resistant-major-depressive-disorder
#19
Brian C Kavanaugh, Scott T Aaronson, Gregory N Clarke, Paul E Holtzheimer, Clark W Johnson, William M McDonald, M Bret Schneider, Linda L Carpenter
BACKGROUND: Neurocognitive dysfunction is an understudied and undertreated aspect of psychiatric research and treatment. There is emerging evidence to suggest that repetitive transcranial magnetic stimulation (rTMS) may possess neurocognition-enhancing capabilities. METHODS: This study examined the neurocognitive data from a randomized, double-blind, sham-controlled trial of an investigational 2-coil rTMS device in antidepressant treatment or treatment-intolerant major depressive disorder patients...
April 2, 2018: Journal of ECT
https://www.readbyqxmd.com/read/29605219/bacterial-pneumonia-in-kidney-transplant-recipients
#20
REVIEW
D Wilmes, E Coche, H Rodriguez-Villalobos, N Kanaan
Bacterial pathogens are the most frequent cause of pneumonia after transplantation. Early after transplantation, recipients are at higher risk for nosocomial infections. The most commonly encountered pathogens during this period are gram-negative bacilli (Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa …), but gram-positive coccus such as Staphylococcus aureus or Streptococcus pneumoniae and anaerobic bacteria can also be found. Empirical antibiotic therapy should be guided by previous colonisation of the recipient and bacterial resistance pattern in the hospital...
April 2018: Respiratory Medicine
keyword
keyword
7313
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"